Drugs / ASKC202
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05306132 | Aug 2022 → Dec 2026 expected | neoplasm | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07109531 | Aug 2025 → Oct 2027 expected | — | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASKC202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05306132 ↗ |
| Route | Oral | “Administration: Oral administration” NCT05306132 ↗ |